title: Treatment of multidrug-resistant tuberculosis in Indonesia.
abstract: There is growing concern, even among developed countries, about the increasing incidence of multidrug-resistant tuberculosis (MDR-TB). Results are reported from a study investigating ofloxacin used in the treatment of 57 patients with MDR-TB. Patients received ofloxacin 400 mg/day as well as three other sensitive anti-TB drugs based on susceptibility tests. Treatment duration was 9 months. Preliminary results of 35 evaluable patients show 55% of MDR-TB cases converted to smear and culture negative within 3 months of therapy. Ofloxacin in combination with other sensitive anti-TB medication shows promise in the treatment of MDR-TB and further studies are recommended.
authors.affiliation: Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jakarta.
authors.forename: M
authors.initials: M
authors.lastname: Hadiarto
authors.forename: Y A
authors.initials: YA
authors.lastname: Tjandra
authors.forename: A
authors.initials: A
authors.lastname: Hudoyo
mesh_terms: D000328:Adult; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007214:Indonesia; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D009325:Nausea / Q000139:chemically induced / Q000150:complications; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D011718:Pyrazinamide; D015242:Ofloxacin; D007538:Isoniazid; D012293:Rifampin